Synopsis
Synopsis
0
KDMF
0
VMF
0
Listed Suppliers
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Amdinocillin Pivoxil
2. Fl 1039
3. Fl-1039
4. Fl1039
5. Hydrochloride, Pivmecillinam
6. Mecillinam Pivaloyl Ester
7. Pivaloyl Ester, Mecillinam
8. Pivamdinocillin
9. Pivmecillinam Hydrochloride
10. Pivoxil, Amdinocillin
11. Selexid
1. Amdinocillin Pivoxil
2. 32886-97-8
3. Pivmecilinamo
4. Pivmecillinamum
5. Selexid
6. Amdinocillin Pivoxil [usan]
7. Pivmecilinamo [inn-spanish]
8. Pivmecillinamum [inn-latin]
9. Ro 10-9071
10. Amdinocillin, Pivaloyloxymethyl Ester
11. Pivmecillinam (inn)
12. Pivmecillinam [inn]
13. 1wam1oq30b
14. Amdinocillin Pivoxil (usan)
15. Ro-10-9071
16. Chebi:51210
17. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl Ester, (2s-(2alpha,5alpha,6beta))-
18. Hydroxymethyl (2s,5r,6r)-6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate Pivalate (ester)
19. Coactabs
20. [(2,2-dimethylpropanoyl)oxy]methyl (2s,5r,6r)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
21. [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate
22. Coactabs (tn)
23. 2,2-dimethylpropanoyloxymethyl (2s,5r,6r)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
24. Ncgc00016813-01
25. Cas-32887-03-9
26. Unii-1wam1oq30b
27. Sr-01000838842
28. Einecs 251-276-6
29. Prestwick0_001053
30. Prestwick1_001053
31. Prestwick2_001053
32. Prestwick3_001053
33. Pivmecillinam [jan]
34. Schembl33907
35. Schembl33908
36. Bspbio_001006
37. Pivmecillinam [mart.]
38. Spbio_002933
39. Pivmecillinam [who-dd]
40. Bpbio1_001108
41. Chembl1525183
42. Chembl1616433
43. Chembl1650818
44. Dtxsid7048538
45. Gtpl10922
46. Amdinocillin Pivoxil [mi]
47. Pivmecillinam, >=98% (hplc)
48. Bcp07843
49. Hy-b0810
50. Zinc4214799
51. Zinc13704173
52. Db01605
53. Ro-109071
54. Ncgc00179344-01
55. Ncgc00179344-04
56. Ncgc00179344-07
57. Ab00514713
58. D02889
59. A918810
60. Q418086
61. Sr-01000838842-2
62. Brd-k67100011-003-03-0
63. (2s,6r)-pivaloyloxymethyl 6-((e)-azepan-1-ylmethyleneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
64. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl Ester, (2s-(2.alpha.,5.alpha.,6.beta.))-
| Molecular Weight | 439.6 g/mol |
|---|---|
| Molecular Formula | C21H33N3O5S |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 439.21409234 g/mol |
| Monoisotopic Mass | 439.21409234 g/mol |
| Topological Polar Surface Area | 114 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 710 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used to treat infections due to mecillinam-sensitive organisms such as urinary tract infections, salmonellosis and typhoid fever.
Pivmecillinam is a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Anti-Infective Agents, Urinary
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01C - Beta-lactam antibacterials, penicillins
J01CA - Penicillins with extended spectrum
J01CA08 - Pivmecillinam
Absorption
Well absorbed following oral administration.
Pivmecillinam interferes with the biosynthesis of the bacterial cell wall however its activity is slightly different from that of other penicillins and cephalosporins
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Drugs in Development
Details:
Pivya (pivmecillinam) oral tablets have been approved by the FDA for treating uncomplicated urinary tract infections (UTIs) in adult females caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Pivya
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves New Treatment for Uncomplicated Urinary Tract Infections
Details : Pivya (pivmecillinam) oral tablets have been approved by the FDA for treating uncomplicated urinary tract infections (UTIs) in adult females caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Brand Name : Pivya
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2024
Details:
The net proceeds will be used for the development and commercialization of two European-approved antibiotics, including Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation, for the treatment of urinary tract infections.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Pivya
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: AMR Action Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 17, 2024
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
Details : The net proceeds will be used for the development and commercialization of two European-approved antibiotics, including Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation, for the treatment of urinary tr...
Brand Name : Pivya
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2024
Details:
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UTILITY Therapeutics to Present Data at IDWeek 2021
Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2021
Details:
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UTILITY Therapeutics Preparing NDA Submission
Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
